Merck expands Januvia label


In a sort of good news/bad news move, the FDA is allowing Merck to expand marketing of the diabetes drug Januvia--but it's also expanding the warnings on Januvia's label.

Now, Merck can sell the drug for use in combo with other diabetes meds, rather than as a supplement to diet and exercise alone. The new label will highlight warnings of hypersensitivity reactions, including the rare-but-deadly Stevens-Johnson syndrome.

- take a look at Merck's release
- read the report from the Houston Chronicle

Read more on: Merck | Januvia

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.